Most DPP-4 inhibitors are eliminated renally (Table 7) and therefore require dose adjustment in CKD (chronic kidney disease), except linagliptin, which is mainly eliminated via the enterohepatic route, and can be used in patients with CKD without dose adjustment [5,83]. Here, DPP4 is linked to chronic kidney disease.